Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07746245 | The Efficacy of CAPCT in Patients With PTCL | not yet recruiting | Phase 2 | 58 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07748455 | HMA-Venetoclax Induction in Newly Diagnosed AML(VENTURE-AML) | not yet recruiting | Phase 2 | 60 | Pakistan Blood and Marrow Transplant (PBMT) GroupOTHER | 1 | Aug 5, 2026 |
| clinicaltrials |
| NCT02143414 | Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia | active not recruiting | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT02213926 | An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma | active not recruiting | Phase 2 | 124 | Acerta Pharma BVINDUSTRY | 10 | Aug 4, 2026 | clinicaltrials |
| NCT03984448 | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas | active not recruiting | Phase 2 / Phase 3 | 363 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06539195 | DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9) | completed | Phase 2 | 59 | Dizal PharmaceuticalsINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06665100 | PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV) | recruiting | Phase 2 | 100 | Pulmotect, Inc.INDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT00006436 | EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection | completed | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 3, 2026 | clinicaltrials |
| NCT04320888 | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 3 | Aug 3, 2026 | clinicaltrials |
| NCT07638683 | A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL). | recruiting | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07743112 | A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia | recruiting | Phase 2 | 43 | Maxinovel Pty., Ltd.INDUSTRY | 1 | Aug 3, 2026 | clinicaltrials |
| NCT03011814 | Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 78 | City of Hope Medical CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03888105 | A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies(ELM-2) | active not recruiting | Phase 2 | 515 | Regeneron PharmaceuticalsINDUSTRY | 14 | Jul 31, 2026 | clinicaltrials |
| NCT04557098 | A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma(MajesTEC-1) | active not recruiting | Phase 2 | 194 | Janssen Research & Development, LLCINDUSTRY | 11 | Jul 31, 2026 | clinicaltrials |
| NCT04617925 | A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis(EMN27) | completed | Phase 2 | 35 | Stichting European Myeloma NetworkNETWORK | 6 | Jul 31, 2026 | clinicaltrials |
| NCT05669989 | International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab | enrolling by invitation | Phase 2 | 70 | SanofiINDUSTRY | 17 | Jul 31, 2026 | clinicaltrials |
| NCT06425302 | A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma(GOLSEEK-2) | active not recruiting | Phase 2 | 95 | CelgeneINDUSTRY | 13 | Jul 31, 2026 | clinicaltrials |
| NCT06965114 | Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia | recruiting | Phase 1 / Phase 2 | 84 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06985147 | A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV) | active not recruiting | Phase 2 | 60 | Disc Medicine, IncINDUSTRY | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07069699 | Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene | recruiting | Phase 1 / Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07738887 | Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations(EVITA) | not yet recruiting | Phase 2 | 44 | The Lymphoma Academic Research OrganisationOTHER | 2 | Jul 31, 2026 | clinicaltrials |
| NCT01134575 | CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) | completed | Phase 2 | 90 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT02727803 | Personalized NK Cell Therapy in CBT | recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT02981628 | Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia | active not recruiting | Phase 2 | 80 | Children's Oncology GroupNETWORK | 2 | Jul 30, 2026 | clinicaltrials |
| NCT03488225 | Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia | terminated | Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04263584 | Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL(COPA-R-CHOP) | completed | Phase 2 | 62 | University Hospital MuensterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04439227 | Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I) | active not recruiting | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04975919 | Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | active not recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06967610 | Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07072585 | Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) | not yet recruiting | Phase 2 / Phase 3 | 1,708 | Children's Oncology GroupNETWORK | 0 | Jul 30, 2026 | clinicaltrials |
| NCT07197307 | Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)(CLEAR) | recruiting | Phase 2 | 120 | Universität MünsterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07548710 | Study of SA+X in the Treatment of Newly Diagnosed AML | recruiting | Phase 2 | 205 | Ruijin HospitalOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07609862 | A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies | recruiting | Phase 1 / Phase 2 | 92 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03075696 | A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma | active not recruiting | Phase 1 / Phase 2 | 940 | Hoffmann-La RocheINDUSTRY | 13 | Jul 29, 2026 | clinicaltrials |
| NCT03264131 | BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma | completed | Phase 2 | 16 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05357794 | Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05827549 | Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia(ReCALL) | recruiting | Phase 2 | 90 | Ho Joon ImOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06184009 | Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia(HR ALL) | recruiting | Phase 2 | 370 | Jae Wook LeeOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06257394 | Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea(VHR ALL) | recruiting | Phase 2 | 74 | Hyoung Jin KangOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06356922 | Study Assessing RLT Using [177Lu]Lu-PentixaTher for Relapsed/Refractory CXCR4+ Acute Leukemia.(PENTILULA) | active not recruiting | Phase 1 / Phase 2 | 21 | Nantes University HospitalOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06516679 | Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia | recruiting | Phase 2 | 40 | Yonsei UniversityOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07397832 | CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL | recruiting | Phase 2 | 58 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07459608 | Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell Lymphoma | not yet recruiting | Phase 2 | 75 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07730515 | Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 176 | Evopoint Biosciences Inc.INDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07732712 | Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells | not yet recruiting | Phase 2 / Phase 3 | 15 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 0 | Jul 29, 2026 | clinicaltrials |
| NCT07735208 | Geriatric Assessment-Guided Treatment Selection in Older Adults With Acute Myeloid Leukemia(ALIGN-AML) | not yet recruiting | Phase 2 | 120 | University of RochesterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT01574274 | SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma | active not recruiting | Phase 2 | 240 | Dana-Farber Cancer InstituteOTHER | 2 | Jul 28, 2026 | clinicaltrials |
| NCT02506933 | Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant | active not recruiting | Phase 2 | 102 | City of Hope Medical CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT03598608 | Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) | terminated | Phase 1 / Phase 2 | 137 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Jul 28, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Aug 5, 2026source: clinicaltrials